Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 26;15(3):774.
doi: 10.3390/cancers15030774.

Surgical Strategies for Combined Hepatocellular-Cholangiocarcinoma (cHCC-CC)

Affiliations
Review

Surgical Strategies for Combined Hepatocellular-Cholangiocarcinoma (cHCC-CC)

Marcus Bahra et al. Cancers (Basel). .

Abstract

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a tumor entity presenting features of hepatocellular and cholangiocellular epithelial differentiation. Due to the likeness between cHCC-CC, HCC and CC, accurate pretherapeutical diagnosis is challenging and advanced stages are prevalent. Radical oncological surgery is the only curative therapeutical option in patients with cHCC-CC. To reach this goal a profound understanding of this rare liver tumor is crucial. Factors such as clinicopathological characteristics, growth patterns and biological behavior are of central importance. To explore onco-surgical strategies and aspects for complete resection of cHCC-CC and to answer important key questions, an extensive review of the literature was conducted to answer the following questions: What are the best surgical options? Is there a significance for nonanatomical resections? Is there a prognostic value of concomitant lymphadenectomy? What about multimodal concepts in local advanced cHCC-CC? The role of minimally invasive liver surgery (MILS) including the role of robotic liver surgery for cHCC-CC will be discussed. While liver transplantation (LT) is standard for patients with unresectable HCC, the role of LT in cHCC-CC patients is still controversial. How can patients with high risk for early tumor recurrence be identified to avoid aggressive surgical treatment without clinical benefit? The comprehensive understanding of this challenging liver tumor will help to improve future treatment options for these patients.

Keywords: combined hepatocellular-cholangiocarcinoma (cHCC-CC); liver; surgical.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Nakanuma Y., Curado M.P., Franceschi S., Gores G., Paradis V., Sripa B., Tsui W.M.S., Wee A. Intrahepatic cholangio-carcinoma. In: Bosman F., Carnerio F., Hruban R., Theise N., editors. WHO Classification of Tumours of the Digestive System. 4th ed. Volume 3. International Agency for Research on Cancer; Lyon, France: 2010. pp. 214–217.
    1. Jarnagin W.R., Weber S., Tickoo S.K., Koea J.B., Obiekwe S., Fong Y., DeMatteo R.P., Blumgart L.H., Klimstra D. Combined hepatocellular and cholangiocarcinoma: Demographic, clinical, and prognostic factors. Cancer. 2002;94:2040–2046. doi: 10.1002/cncr.10392. - DOI - PubMed
    1. Yano Y., Yamamoto J., Kosuge T., Sakamoto Y., Yamasaki S., Shimada K., Ojima H., Sakamoto M., Takayama T., Makuuchi M. Combined Hepatocellular and Cholangiocarcinoma: A Clinicopathologic Study of 26 Resected Cases. Jpn. J. Clin. Oncol. 2003;33:283–287. doi: 10.1093/jjco/hyg056. - DOI - PubMed
    1. Ng I.O., Shek T.W., Nicholls J., Ma L.T. Combined hepatocellular-cholangiocarcinoma: A clinicopathological study. J. Gastroenterol. Hepatol. 1998;13:34–40. doi: 10.1111/j.1440-1746.1998.tb00542.x. - DOI - PubMed
    1. Lee J.-H., Chung G.E., Yu S.J., Hwang S.Y., Kim J.S., Kim H.Y., Yoon J.-H., Lee H.-S., Yi N.-J., Suh K.-S., et al. Long-term Prognosis of Combined Hepatocellular and Cholangiocarcinoma After Curative Resection Comparison with Hepatocellular Carcinoma and Cholangiocarcinoma. J. Clin. Gastroenterol. 2011;45:69–75. doi: 10.1097/MCG.0b013e3181ce5dfa. - DOI - PubMed

LinkOut - more resources